SMC gives positive decision on Dovato (dolutegravir/lamivudine).


  • Jo Whelan
  • Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Scottish patients have become the first in the UK to have access to Dovato (dolutegravir/lamivudine), after positive advice from The Scottish Medicines Consortium (SMC). Dovato is a once-daily, single-tablet, two-drug regimen that combines the integrase strand transfer inhibitor, dolutegravir, with the nucleoside analogue reverse transcriptase inhibitor, lamivudine.

The SMC issued positive advice for Dovato for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.

  • It noted that in patients for whom this combination regimen is appropriate, Dovato offers a single tablet at no additional cost compared with the two individual components.
  • The advice takes account of a Patient Access Scheme that improves the cost-effectiveness of dolutegravir / lamivudine, and is contingent upon the continuing availability of the scheme in NHS Scotland or a list price that is equivalent or lower.

Dr Rak Nandwani, Chair of the Scottish HIV Clinical Leads said: “Owing to treatment advances, people living with HIV are healthier and living longer than ever before. Individuals with undetectable viral load cannot pass it on. I’m pleased that Scotland continues to lead the way in the UK in terms of providing new options to both prevent and treat HIV. The SMC decision for Dovato offers a new type of treatment option with fewer agents compared to the current standard of taking a daily three-drug regimen. Dovato also has the potential to offer further cost savings to NHS Scotland, in addition to the large savings which we have managed to achieve in recent years.”